Benzinga | Oct 21, 2020 06:34AM EDT

BiomX Highlights Presentation Of Preclinical Data From Its Phage Panel At Infectious Disease Society of America IDWeek Conference 2020

NESS ZIONA, Israel--(BUSINESS WIRE)-- BiomX Inc. (NYSE:PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today presented preclinical data from its phage panel for the treatment of inflammatory bowel disease at the Infectious Disease Society of America (IDSA) Infectious Disease Week (IDWeek) 2020 conference. The poster presentation details a phage therapy panel, comprised of phage directed against Klebsiella pneumoniae, showing a broad target host range and the potential to address carbapenem-resistant and extended spectrum beta-lactamase (ESBL)-producing bacteria.

Acute infections caused by resistant Klebsiella bacteria are recognized as a public health concern by various national and international authorities and organizations, including those providing grant-based funding for novel approaches to treatment. The World Health Organization classifies carbapenem-resistant and ESBL-producing Enterobacteriaceae, which include Klebsiella pneumoniae, as a critical threat, the highest threat level.

Abstract Title Activity of bacteriophage against multidrug resistant Klebsiella pneumoniae (Poster #1564)

Session Treatment of Antimicrobial Resistant Infections

Lead Author Sailaja Puttagunta, M.D., CMO of BiomX